Effects of Fish Restoration Practices on Amphibians in Yellowstone National Park, Wyoming

Throughout the Western United States, fisheries managers are attempting to restore native cutthroat trout (Onchorynchus clarkii) populations by removing nonnative fish species. A new formulation of the EPA approved piscicide rotenone (CFT Legumine) is increasingly being used as a method to accomplish this removal. Because fish restoration projects bring about an abrupt change to aquatic environments, it is important to consider their immediate and long-term effects on non-target species, such as amphibians. We assessed the effects of fish removal on amphibians in Yellowstone National Park (YNP) by investigating the toxicity of rotenone to and the long-term impacts of removing fish on local amphibian populations. CFT Legumine (5% rotenone) was applied to High Lake in YNP (2006) to remove stocked Yellowstone cutthroat trout (O. c. bouvieri). To determine toxicity, amphibian surveys were conducted immediately prior to the treatment to obtain pre-treatment tadpole population estimates. Post-treatment surveys were conducted both immediately, for assessing treatment-related mortality (during and after application), and 1, 2, and 3 years following to obtain tadpole abundance estimates in the years after application and to address the long-term effects of fish removal and reintroduction. The results of the toxicity trials revealed that in the 24 hrs following application, rotenone was lethal to gill-breathing amphibian tadpoles and nonlethal to non-gill breathing metamorphs, juveniles, and adults. In the years following, tadpole repopulation occurred at levels above the pre-treatment abundance estimate, though both tadpole abundance and distribution appeared correlated with fish presence

Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers.

BACKGROUND: Ticagrelor is an oral P2Y12 inhibitor that is used with aspirin to reduce the risk of ischemic events among patients with acute coronary syndromes or previous myocardial infarction. Spontaneous major bleeding and bleeding associated with urgent invasive procedures are concerns with ticagrelor, as with other antiplatelet drugs. The antiplatelet effects of ticagrelor cannot be reversed with platelet transfusion. A rapid-acting reversal agent would be useful. METHODS: In this randomized, double-blind, placebo-controlled, phase 1 trial, we evaluated intravenous PB2452, a monoclonal antibody fragment that binds ticagrelor with high affinity, as a ticagrelor reversal agent. We assessed platelet function in healthy volunteers before and after 48 hours of ticagrelor pretreatment and again after the administration of PB2452 or placebo. Platelet function was assessed with the use of light transmission aggregometry, a point-of-care P2Y12 platelet-reactivity test, and a vasodilator-stimulated phosphoprotein assay. RESULTS: Of the 64 volunteers who underwent randomization, 48 were assigned to receive PB2452 and 16 to receive placebo. After 48 hours of ticagrelor pretreatment, platelet aggregation was suppressed by approximately 80%. PB2452 administered as an initial intravenous bolus followed by a prolonged infusion (8, 12, or 16 hours) was associated with a significantly greater increase in platelet function than placebo, as measured by multiple assays. Ticagrelor reversal occurred within 5 minutes after the initiation of PB2452 and was sustained for more than 20 hours (P\u3c0.001 after Bonferroni adjustment across all time points for all assays). There was no evidence of a rebound in platelet activity after drug cessation. Adverse events related to the trial drug were limited mainly to issues involving the infusion site. CONCLUSIONS: In healthy volunteers, the administration of PB2452, a specific reversal agent for ticagrelor, provided immediate and sustained reversal of the antiplatelet effects of ticagrelor, as measured by multiple assays. (Funded by PhaseBio Pharmaceuticals; ClinicalTrials.gov number, NCT03492385.)

A Soil Parameters Geodatabase for the Modeling Assessment of Agricultural Conservation Practices Effects in the United States

Soil parameters for hydrology modeling in cropland dominated areas, from the regional to local scale, are part of critical biophysical information whose deficiency may increase the uncertainty of simulated conservation effects and predicting potential. Despite this importance, soil physical and hydraulic parameters lack common, wide-coverage repositories combined to digital maps as required by various hydrology-based agricultural water quality models. This paper describes the construction of a geoprocessing workflow and the resultant hydrology-structured soil hydraulic, physical, and chemical parameters geographic database for the entire United States, named US-SOILM-CEAP. This database is designed to store a-priori values for a suit of models, such as SWAT (Soil and Water Assessment Tool), APEX (Agricultural Policy Environmental EXtender) and ALMANAC (Agricultural Land Management Alternatives with Numerical Assessment Criteria), which are commonly used for the across scale assessment of agricultural hydrology and conservation practice scenarios. The Soil Survey Geographic (SSURGO) database developed by the U.S. Department of Agriculture provided the main source data for this development. Additional spatial information, a geographic information system platform and Python computer programming language code were used to create hydrology-based tile coverage of the areal soil units linked to the specific and detailed attributes required by each model. The created repository adds value to the source soil survey data, while maintaining and extending the detailed information necessary for the across scale and combined application of the models. Ultimately, our multi-model database provides a comprehensive product achieving joined informational-mapping-geoprocessing functionality with the explicit maintenance of the original conceptual links between soil series and composing soil layers, allowing for efficient data retrieval, analysis and service as input for modeling conservation effects

Enteropathogen antibody dynamics and force of infection among children in low-resource settings.

Little is known about enteropathogen seroepidemiology among children in low-resource settings. We measured serological IgG responses to eight enteropathogens (Giardia intestinalis, Cryptosporidium parvum, Entamoeba histolytica, Salmonella enterica, enterotoxigenic Escherichia coli, Vibrio cholerae, Campylobacter jejuni, norovirus) in cohorts from Haiti, Kenya, and Tanzania. We studied antibody dynamics and force of infection across pathogens and cohorts. Enteropathogens shared common seroepidemiologic features that enabled between-pathogen comparisons of transmission. Overall, exposure was intense: for most pathogens the window of primary infection was <3 years old; for highest transmission pathogens primary infection occurred within the first year. Longitudinal profiles demonstrated significant IgG boosting and waning above seropositivity cutoffs, underscoring the value of longitudinal designs to estimate force of infection. Seroprevalence and force of infection were rank-preserving across pathogens, illustrating the measures provide similar information about transmission heterogeneity. Our findings suggest antibody response can be used to measure population-level transmission of diverse enteropathogens in serologic surveillance

Metal and nanoparticle occurrence in biosolid-amended soils

Metals can accumulate in soils amended with biosolids in which metals have been concentrated during wastewater treatment. The goal of this study is to inspect agricultural sites with long-term biosolid application for a suite of regulated and unregulated metals, including some potentially present as commonly used engineered nanomaterials (ENMs). Sampling occurred in fields at a municipal and a privately operated biosolid recycling facilities in Texas. Depth profiles of various metals were developed for control soils without biosolid amendment and soils with different rates of biosolid application (6.6 to 74 dry tons per hectare per year) over 5 to 25 years. Regulated metals of known toxicity, including chromium, copper, cadmium, lead, and zinc, had higher concentrations in the upper layer of biosolid-amended soils (top 0–30 cm or 0–15 cm) than in control soils. The depth profiles of unregulated metals (antimony, hafnium, molybdenum, niobium, gold, silver, tantalum, tin, tungsten, and zirconium) indicate higher concentrations in the 0–30 cm soil increment than in the 70–100 cm soil increment, indicating low vertical mobility after entering the soils. Titanium-containing particles between 50 nm and 250 nm in diameterwere identified in soil by transmission electron microscopy (TEM) coupled with energy dispersive x-ray spectroscopy (EDX) analysis. In conjunctionwith other studies, this research shows the potential for nanomaterials used in society that enter the sewer system to be removed at municipal biological wastewater treatment plants and accumulate in agricultural fields. The metal concentrations observed herein could be used as representative exposure levels for eco-toxicological studies in these soils

Convenient Synthesis of Copper (I) Thiolates and Related Compounds

Copper (I) salts of various anions including thiolates, diethyl dithiocarbamate, diethyl dithiophosphate, trithiocyanurate, 1-cyano-3-methylisothiourea, 2-aminothiazole, and tetrakis(1-imidazolyl)borate are conveniently synthesized by reducing copper (II) sulfate in aqueous ammonia. The addition of phosphine ligands to several of the products is demonstrated, and the crystal structure of [Cu2(MBT)2(DPPE)3] · Et2O (MBT = 2-mercaptobenzothiazolate, DPPE = 1,2-bis(diphenylphosphino)ethane) is reported

Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program

Esdeveniments adversos; Esclerosi múltiple; OzanimodEventos adversos; Esclerosis múltiple; OzanimodAdverse events; Multiple sclerosis; OzanimodBackground Ozanimod, an oral sphingosine 1-phosphate receptor 1 and 5 modulator, is approved in multiple countries for the treatment of relapsing multiple sclerosis (RMS). In phase 3 trials, ozanimod was well tolerated and superior to interferon beta-1a 30 µg once-weekly in reducing clinical and radiologic disease activity. The objective of this integrated safety analysis was to evaluate the safety of extended ozanimod exposure in participants with RMS from all clinical trials and compare it with phase 3 trial data. Methods We report pooled incidence and study duration‒adjusted incidence rates (IR) of treatment-emergent adverse events (TEAEs) from an interim data cut (January 31, 2019) of RMS participants treated with ozanimod. Data were pooled from a phase 1 pharmacokinetic/pharmacodynamic trial, a placebo-controlled phase 2 trial with dose-blinded extension, 2 large active-controlled phase 3 trials, and an open-label extension (OLE). Results were compared with pooled phase 3 trial data. Results At the data cutoff, 2631 RMS participants had exposure to ozanimod 0.92 mg (mean 32.0 months) and 2787 had exposure to either ozanimod 0.46 or 0.92 mg (mean 37.1 months). The IRs per 1000 person-years (PY) for any TEAE (772.2) and serious TEAEs (33.2) in the overall population were similar to those in the phase 3 population (896.1 and 31.2, respectively). There were no serious opportunistic infections. There were no second-degree or higher atrioventricular blocks on electrocardiogram. Hepatic enzyme elevations declined over time. Malignancy rates remained low with longer exposure. Pulmonary function tests showed minimal reductions in lung function. Seven ozanimod-treated participants with comorbid risk factors had confirmed macular edema, including 3 in the ongoing OLE. Conclusions Safety results in this larger RMS population with greater ozanimod exposure demonstrated no new safety concerns and were consistent with phase 3 trial results

Iatrogenic Spinal Cord Injury Resulting From Cervical Spine Surgery.

STUDY DESIGN: Retrospective cohort study of prospectively collected data. OBJECTIVE: To examine the incidence of iatrogenic spinal cord injury following elective cervical spine surgery. METHODS: A retrospective multicenter case series study involving 21 high-volume surgical centers from the AOSpine North America Clinical Research Network was conducted. Medical records for 17 625 patients who received cervical spine surgery (levels from C2 to C7) between January 1, 2005, and December 31, 2011, were reviewed to identify occurrence of iatrogenic spinal cord injury. RESULTS: In total, 3 cases of iatrogenic spinal cord injury following cervical spine surgery were identified. Institutional incidence rates ranged from 0.0% to 0.24%. Of the 3 patients with quadriplegia, one underwent anterior-only surgery with 2-level cervical corpectomy, one underwent anterior surgery with corpectomy in addition to posterior surgery, and one underwent posterior decompression and fusion surgery alone. One patient had complete neurologic recovery, one partially recovered, and one did not recover motor function. CONCLUSION: Iatrogenic spinal cord injury following cervical spine surgery is a rare and devastating adverse event. No standard protocol exists that can guarantee prevention of this complication, and there is a lack of consensus regarding evaluation and treatment when it does occur. Emergent imaging with magnetic resonance imaging or computed tomography myelography to evaluate for compressive etiology or malpositioned instrumentation and avoidance of hypotension should be performed in cases of intraoperative and postoperative spinal cord injury

Epidural Hematoma Following Cervical Spine Surgery.

STUDY DESIGN: A multicentered retrospective case series. OBJECTIVE: To determine the incidence and circumstances surrounding the development of a symptomatic postoperative epidural hematoma in the cervical spine. METHODS: Patients who underwent cervical spine surgery between January 1, 2005, and December 31, 2011, at 23 institutions were reviewed, and all patients who developed an epidural hematoma were identified. RESULTS: A total of 16 582 cervical spine surgeries were identified, and 15 patients developed a postoperative epidural hematoma, for a total incidence of 0.090%. Substantial variation between institutions was noted, with 11 sites reporting no epidural hematomas, and 1 site reporting an incidence of 0.76%. All patients initially presented with a neurologic deficit. Nine patients had complete resolution of the neurologic deficit after hematoma evacuation; however 2 of the 3 patients (66%) who had a delay in the diagnosis of the epidural hematoma had residual neurologic deficits compared to only 4 of the 12 patients (33%) who had no delay in the diagnosis or treatment (P = .53). Additionally, the patients who experienced a postoperative epidural hematoma did not experience any significant improvement in health-related quality-of-life metrics as a result of the index procedure at final follow-up evaluation. CONCLUSION: This is the largest series to date to analyze the incidence of an epidural hematoma following cervical spine surgery, and this study suggest that an epidural hematoma occurs in approximately 1 out of 1000 cervical spine surgeries. Prompt diagnosis and treatment may improve the chance of making a complete neurologic recovery, but patients who develop this complication do not show improvements in the health-related quality-of-life measurements